Nav: Home

Possible correlation shown between TMI nuclear accident and thyroid cancers

May 31, 2017

Penn State College of Medicine researchers have shown, for the first time, a possible correlation between the partial meltdown of the Three Mile Island Nuclear Generating Station and thyroid cancers in the counties surrounding the plant.

Three Mile Island (TMI), located near Harrisburg, Pennsylvania, had a partial meltdown accident on March 28, 1979. During the accident, radiation was released into the environment, which the United States Nuclear Regulatory Commission said was in small amounts with no detectable health effects.

Looking at tumor samples from people verified to have lived in the areas around TMI at the time of the accident, remained in the area and subsequently developed thyroid cancer, researchers observed a shift in cases to cancer mutations consistent with radiation exposure, from those consistent with random causes.

In this retrospective cohort study -- meaning the patients in the study already had thyroid cancer and were known to have been exposed to the TMI accident -- lead researcher David Goldenberg, professor of surgery, and colleagues identified 44 patients who were treated at the Penn State Milton S. Hershey Medical Center for the most common type of thyroid cancer -- papillary thyroid cancer -- between 1974 and 2014. The patients were then divided into two groups: at-risk and control groups.

Patients in the at-risk group were those who developed cancer between 1984 and 1996, consistent with known latency periods of radiation-induced thyroid cancer, and who lived in at-risk geographical areas -- based on reported weather patterns -- at the time of the accident.

"This definition was designed to allow us to identify relatively acute effects of radiation exposure from the accident," said Goldenberg.

Patients who developed cancer outside of the expected latency period were placed in the control group.

Researchers searched through all thyroid cancer tumor samples in the hospital's possession from the study period for patients who lived in at-risk regions Dauphin, York, eastern Cumberland, Lancaster and western Lebanon counties. They used genealogical software to verify that the patient was in an at-risk area during the accident, remained until cancer developed and was treated at the Medical Center. The tumor samples of those patients who were positively linked to the TMI accident area were then processed through the Penn State Institute for Personalized Medicine to determine genetic makeup of the cancer.

While most thyroid cancers are sporadic, meaning they happen without clear reasons, exposure to radiation has been shown to change the molecular makeup of the cancer, according to the researchers.

The researchers observed an increase in the genetic mutation caused by exposure to low-dose radiation in the at-risk group and a decrease in the incidence of sporadic thyroid cancer, identified by a specific genetic mutation known as BRAF. The BRAF mutation is typically not present in the radiation-induced types of thyroid cancer.

The study, which appeared in the May 29 supplement to the journal Laryngoscope, indicates that these observations are consistent with other radiation-exposed populations.

In the control group, 83 percent of patients had the BRAF mutation. The BRAF mutation was found in only 53 percent of patients in the at-risk group. In the at-risk group, there was also a rise in other molecular markers seen in radiation-induced thyroid cancer, the researchers added.

"While no single marker can determine whether an individual tumor is radiation-induced, these data support the possibility that radiation released from TMI altered the molecular profile of thyroid cancers in the population surrounding the plant," Goldenberg said.

A limitation of this study is the small sample size, limited to tumor samples from patients treated for thyroid cancer at Penn State Health Milton S. Hershey Medical Center. The next step in the research is a study with a larger number of patients from other regional hospitals to determine if the correlation continues in a larger sample.

"All patients were screened extensively to ensure that they lived in the vicinity of TMI from the date of the accident until they developed thyroid cancer," Goldenberg said. "We used an extensive vetting process to ensure that patients included in the study were present in at-risk counties at the time of the accident and to confirm, to the greatest extent possible, that patients resided in affected areas for their entire lives. Our study represents a static population, which increased our ability to detect radiation-induced cancers."

Past studies about thyroid cancer and TMI have showed variable results, mainly because they were demographic studies that looked at the entire population and not just those who met the criteria of the current study.

"Much of the variability associated with these studies is likely due to the relatively small size of the population surrounding the TMI plant relative to the large population required to detect statistically significant increases in cancer incidence following low-level radiation, combined with a high degree of mobility in the local population," Goldenberg said.
Other researchers who participated in this study include: Mariano Russo, biomedical sciences graduate program; Kenneth Houser, research technologist; Henry Crist, M.D., associate professor of pathology; Jonathan B. Derr, research technologist ; Vonn Walters, Ph.D., assistant professor of biochemistry and molecular biology; Joshua Warrick, M.D., assistant professor of pathology; Kathryn E. Sheldon, Ph.D., research project manager; James Broach, Ph.D., chair, biochemistry and molecular biology; Darrin V. Bann, M.D., Ph.D., surgery resident.

The George Laverty Foundation funded this research.

Penn State

Related Cancer Articles:

Radiotherapy for invasive breast cancer increases the risk of second primary lung cancer
East Asian female breast cancer patients receiving radiotherapy have a higher risk of developing second primary lung cancer.
Cancer genomics continued: Triple negative breast cancer and cancer immunotherapy
Continuing PLOS Medicine's special issue on cancer genomics, Christos Hatzis of Yale University, New Haven, Conn., USA and colleagues describe a new subtype of triple negative breast cancer that may be more amenable to treatment than other cases of this difficult-to-treat disease.
Metabolite that promotes cancer cell transformation and colorectal cancer spread identified
Osaka University researchers revealed that the metabolite D-2-hydroxyglurate (D-2HG) promotes epithelial-mesenchymal transition of colorectal cancer cells, leading them to develop features of lower adherence to neighboring cells, increased invasiveness, and greater likelihood of metastatic spread.
UH Cancer Center researcher finds new driver of an aggressive form of brain cancer
University of Hawai'i Cancer Center researchers have identified an essential driver of tumor cell invasion in glioblastoma, the most aggressive form of brain cancer that can occur at any age.
UH Cancer Center researchers develop algorithm to find precise cancer treatments
University of Hawai'i Cancer Center researchers developed a computational algorithm to analyze 'Big Data' obtained from tumor samples to better understand and treat cancer.
New analytical technology to quantify anti-cancer drugs inside cancer cells
University of Oklahoma researchers will apply a new analytical technology that could ultimately provide a powerful tool for improved treatment of cancer patients in Oklahoma and beyond.
Radiotherapy for lung cancer patients is linked to increased risk of non-cancer deaths
Researchers have found that treating patients who have early stage non-small cell lung cancer with a type of radiotherapy called stereotactic body radiation therapy is associated with a small but increased risk of death from causes other than cancer.
Cancer expert says public health and prevention measures are key to defeating cancer
Is investment in research to develop new treatments the best approach to controlling cancer?
UI Cancer Center, Governors State to address cancer disparities in south suburbs
The University of Illinois Cancer Center and Governors State University have received a joint four-year, $1.5 million grant from the National Cancer Institute to help both institutions conduct community-based research to reduce cancer-related health disparities in Chicago's south suburbs.
Leading cancer research organizations to host international cancer immunotherapy conference
The Cancer Research Institute, the Association for Cancer Immunotherapy, the European Academy of Tumor Immunology, and the American Association for Cancer Research will join forces to sponsor the first International Cancer Immunotherapy Conference at the Sheraton New York Times Square Hotel in New York, Sept.

Related Cancer Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Failure can feel lonely and final. But can we learn from failure, even reframe it, to feel more like a temporary setback? This hour, TED speakers on changing a crushing defeat into a stepping stone. Guests include entrepreneur Leticia Gasca, psychology professor Alison Ledgerwood, astronomer Phil Plait, former professional athlete Charly Haversat, and UPS training manager Jon Bowers.
Now Playing: Science for the People

#524 The Human Network
What does a network of humans look like and how does it work? How does information spread? How do decisions and opinions spread? What gets distorted as it moves through the network and why? This week we dig into the ins and outs of human networks with Matthew Jackson, Professor of Economics at Stanford University and author of the book "The Human Network: How Your Social Position Determines Your Power, Beliefs, and Behaviours".